44 results about "Ocular tissue" patented technology

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

Provided is a composition for visual field defect disorders, glaucoma, light-induced ocular tissue damage and related disorders, which can be used as a food or drug for long-term administration, prevention, symptom relief and improvement. A composition comprising a triglyceride represented by the formula (I):(wherein R1, R2, and R3 are each a saturated fatty acid residue, and at least one of them is a pentadecanoic acid residue) as an active ingredient.

A method of treating an eye includes delivering an OCT beam along an OCT optical path that enters a first optical subsystem along an input axis, and exits the first optical subsystem along an output axis that: 1) is substantially parallel to the optical axis of the eye, 2) is radially offset from the optical axis, and 3) extends through the cornea and into a portion of the irido-corneal angle at a point along a circumferential angle of the eye. The method also includes imaging the portion of the irido-corneal angle with the OCT beam; delivering a laser beam along an angled optical path that extends through the first optical subsystem, through the cornea, through the anterior chamber, and into a target volume of ocular tissue in the portion of the irido-corneal angle; and photodisrupting at least a portion of the target volume of ocular tissue with the laser beam.

This invention relates to a biopsy needle for trabecular meshwork tissue of the eye, belonging to the field of medical device technology. It solves the problem of large incisions caused by the large surgical incisions in traditional trabeculectomy procedures, where a scalpel is used to cut a block of ocular tissue containing the trabeculae and deep cornea and sclera. The invention includes a needle, a scraper unit, and a handle. The needle is connected to the handle, the scraper unit is disposed within the needle, and the handle is for the user to hold. The needle is inserted into the patient's eyeball, and the scraper unit is used to cut the trabecular meshwork and Schlemm's canal wall tissue. The scraper unit of this invention is a bendable scraper unit. The first, second, and third sections can form grooved hooks for hooking the trabecular meshwork and Schlemm's canal wall tissue. The grooved hooks of this invention are specifically designed to hook the trabecular meshwork and Schlemm's canal wall tissue, resulting in minimal trauma to the ocular incision.

The invention discloses a three-dimensional reconstruction method and system for eye tissue, medical equipment and a storage medium. The method comprises the steps that at least two OCT images are acquired; determining a tissue boundary line of the target eye tissue based on the at least two OCT images; generating a mask of the target eye tissue based on the at least two OCT images; and generating a three-dimensional reconstruction model of the target eye tissue based on the tissue boundary line and the mask.

Disclosed are methods, systems, media, apparatus, devices, and other implementations, including a method that includes determining blood flow characteristics at an ocular surface of an eye of a patient, determining characteristics of blood vessels at the ocular surface of the eye based on the determined blood flow characteristics, and deriving one or more ocular redness grading scales indicative of inflammation levels of the eye of the patient based on the determined characteristics of the blood vessels at the ocular surface of the eye.

Disclosed is a glaucoma device (10, 1010) comprising: an implant body (15, 1015) including an anterior portion (20, 1020), a distal portion (35, 1035), a plurality of arms (40, 1040) extending between the anterior portion (20, 1020) and the distal portion (35, 1035) to provide connection therebetween; and a fluid network extending from the anterior portion (20, 1020) along at least one of the arms (40, 1040) to the distal portion (35, 1035), the fluid network providing a plurality of outlet channels (90, 1090) for fluid exit therefrom; and a fluid inlet cannula (30, 1030) arranged on the anterior portion (20, 1020) of the implant body (15, 1015) and adapted for fluid connection with ocular tissue.

An ab externo automated laser treatment system for treating an eye in a subject, includes a non-contact laser source configured to generate a laser beam having at least one wavelength to treat the eye by directing the laser beam from a location spaced from the eye, wherein the at least one wavelength is a near-infrared wavelength in the range of about 0.5-2.2 μm, a laser scanner optically coupled to the non-contact laser source to receive the laser beam from the non-contact laser source and to scan the laser beam relative to the eye, and a processor, and memory including stored computer-readable instructions that, responsive to execution by the processor, cause the laser treatment system to direct the laser beam to a plurality of trans-scleral treatment locations to be irradiated in a predetermined treatment pattern on an external surface of the eye, wherein the trans-scleral treatment locations are 0-4 mm posterior to the corneolimbal junction, and wherein the laser beam is repetitively directed to the same irradiated trans-scleral treatment locations on the surface of the eye, and the trans-scleral treatment locations are irradiated at intervals sufficient to induce protective thermal preconditioning and therapeutic bio-stimulation of one or more of the trabecular meshwork and / or ciliary body without photocoagulation of the tissue of the eye. Trans-pupillary systems, patient interfaces, and methods are also disclosed.

The utility model provides an iris dilation ring, which relates to the technical field of ophthalmologic operation related equipment, and comprises a dilation ring body and a connecting band assembly, the dilation ring body is of an unclosed circular ring structure, and the dilation ring body is used for penetrating through an incision of an eyeball and being attached to an iris so as to assist in dilation of the iris; the connecting belt assembly is detachably connected with the dilation ring body, and the connecting belt assembly is arranged on the outer side of the incision so as to prevent the dilation ring body from falling off from the iris. The technical problem that in the prior art, when an eye operation is carried out, eye tissue is prone to being damaged is solved.

Apparatuses and methods for facilitating the guided delivery of a drug into a patient's body organ are disclosed. An apparatus (2500) for facilitating the guided delivery of a drug into a patient's body organ can include a container (2504) configured to package a drug, a needle (2502) having a passage therethrough and a sharp distal tip, and a needle sheath (2506) at least partially surrounding a shaft of the needle. The needle sheath can include a distal surface, wherein the sharp distal tip of the needle can be configured to extend through an opening in the distal surface. The needle sheath can be movable relative to the needle along an axis of the needle to control a distance from the distal surface to the distal tip of the needle.

An optical coherence tomography (OCT) scanning system for measuring ocular tissue characteristics of an eye of a patient. The system includes an OCT scanner configured to implement a scan sequence on ocular tissue that scans the ocular tissue with an optical signal to obtain OCT data based on a reflected version of the optical signal. The system includes a computer having a processor configured to provide a control signal to the OCT scanner to implement a sequence of scans and determine a rate of change of phase data or amplitude data associated with the scans. The system determines a growth constant for a reflected version of the optical signal based on a rate of change of the phase data or amplitude data, and determines a diffusion coefficient associated with the cornea based on the growth constant. The system determines quantitative parameters of the cornea based on the diffusion coefficients.

Certain aspects of the present disclosure provide systems and methods for measuring ocular tissue biomechanics via blink stimulation. In some embodiments, a method may be performed by a computer in communication with an optical coherence tomography (OCT) device. The method includes monitoring movement relative to an eye of a patient via one or more images from a camera. The method also includes detecting a blink of the eye of the patient in response to the monitoring. The method further includes, in response to the detected blink, recording data resulting from a scan of at least a portion of the tissue of the eye by the OCT device. The method further includes measuring a response of the tissue to the detected blink based on the recorded data from the scan.

Disclosed are devices and methods for directed delivery of a medicament into ocular tissue. A device for delivering a medicament to ocular tissue may include a housing, a container configured to contain the medicament, and a needle in fluid communication with the container, and a carriage positioned within the housing and coupled to the container and the needle. The carriage may be translatable along the needle axis and the carriage may include a threaded outer surface. The device may further include a nut positioned within the housing and engaged with the threaded outer surface. Rotation of the nut may be configured to cause the carriage and the needle to translate in a distal direction along the needle axis.

The invention discloses an intelligent implantable glasses system based on a brain-computer interface and optical imaging, relates to the technical field of nerve regulation and control, and solves the problem of poor adaptability of a rigid substrate by adopting a specific flexible substrate and a multi-layer coating structure through a flexible implantation carrier module to adapt to eyeballs or periorbital tissues; the multi-modal sensing decoding module integrates multiple types of sensors and a fusion algorithm, so that multi-dimensional signal capture and cooperative decoding are realized, and the limitation of single-modal signal decoding is overcome; the closed-loop control function module constructs a closed-loop regulation and control link, dynamically adjusts parameters according to the physiological state of a user, and changes a traditional open-loop control mode; the wireless energy supply encryption module is integrated with a wireless energy supply and encryption communication assembly, stable energy transmission and signal security encryption are achieved, and the problems of separation of wireless communication and an energy supply module and potential data safety hazards are solved. And the external terminal interaction module is linked with the implantation side module through a wireless link to realize cooperative work.

An ophthalmological device comprises a laser source, an application head having focusing optics and a patient interface, a scanner system and circuit. The circuit is configured to control the scanner system to incise an incision surface, which is symmetrical with respect to the central axis of the patient interface, in the eye tissue, a pulsed laser beam being steered onto treatment points on the incision surface on a first treatment path, and the treatment path being curved while extending around the projection axis of the focusing optics. In the event of a tilt of the eye with respect to the central axis of the patient interface, the circuit determines an apex of a tilted incision surface by a co-tilt of the incision surface corresponding to the tilt of the eye, and determines a transformed treatment path, which extends around the apex and determines treatment points on the tilted incision surface.

The application relates to an intelligent ophthalmic ultrasonic emulsifier and a use method, and belongs to the technical field of ophthalmic surgical instruments, which comprises a main machine body, an operating handle, an anchor component and a viscosity type self-locking mechanism, an ultrasonic amplitude rod, a perfusion pipeline and a suction pipeline are arranged in the operating handle, an emulsification needle head and a perfusion sleeve are arranged at one end of the operating handle, a liquid inlet chamber is formed between the emulsification needle head and the perfusion sleeve, the anchor component is arranged in the liquid inlet chamber and is used for anchoring a hard nucleus in front of an opening of the emulsification needle head, and the viscosity type self-locking mechanism is arranged in the suction pipeline and comprises a hairspring disc body provided with a plurality of micropores; the hairspring disc body is configured to be deformed to block the suction pipeline when a high-viscosity fluid cannot pass through the micropores; the hard nucleus is anchored by the anchor component, so that the ocular tissue is prevented from being damaged by the rebound of the nucleus block; meanwhile, the viscosity type self-locking mechanism is used for instantaneously blocking the suction pipeline when the vitreous body is sucked, so that the retina is prevented from being damaged by traction, and the surgical safety and efficiency are improved.

Certain aspects of the present disclosure provide systems (10) and methods (800) for real-time measurement of biomechanics at a plurality of ocular tissue locations. In some embodiments, the method (800) may be performed by a computer (30) in communication with an optical coherence tomography (OCT) device (15, 315). The method includes receiving an indication that stimulation is applied to ocular tissue (346) of a patient (42). The method further includes instructing the OCT device (15, 315) to emit a plurality of light beams (344, 560, 660) to a plurality of measurement locations (772) on the ocular tissue (346) at substantially the same time in response to the received indication. The method (800) also includes receiving OCT data for each of the plurality of measurement locations (772) from the OCT device (15, 315). The method (800) also includes measuring a tissue response to the stimulation at the plurality of measurement locations based on the OCT data.

The invention relates to a cornea diameter determination method and device, equipment, a storage medium and a program product. The method comprises the following steps: acquiring an eye image of an examined eye acquired by a pupil camera, and determining eye tissue information corresponding to each eye tissue of the examined eye based on the eye image; determining an iris region and a sclera region according to the eye tissue information corresponding to each eye tissue; a sclera boundary is determined according to the iris region and the sclera region, a plurality of target pixel points are determined according to coordinates of pixel points on the sclera boundary and gradient values corresponding to the pixel points on the sclera boundary, and the target pixel points are pixel points with the gradient values being extreme values in pixel rows where the target pixel points on the sclera boundary are located; and determining the cornea diameter according to each target pixel point. By adopting the method, the accuracy of cornea diameter determination can be improved.

1. Name of the product in this design: Glass cutting head (statically indeterminate needle device). 2. Purpose of this design: To connect to ophthalmic vitrectomy equipment and to serve as a vitrectomy head for cutting the vitreous body and eye tissues. 3. The key design feature of this product is its shape. 4. The picture or photo that best illustrates the key design points: Design 1 3D diagram 1. 5. Design 1 is designated as the basic design. 6. The product in this design is a long and slender item, and its length is drawn using an abbreviated method.

The application discloses application of TAPI-1 in preparation of a drug for treating dry age-related macular degeneration, and belongs to the technical field of biological medicine. A dry age-related macular degeneration mouse model is constructed by using sodium iodate, and a TAPI-1 solution is injected into the vitreous body for treatment, and structural examination and histopathological examination are conducted on the mouse. The experimental results show that, compared with the control group, the retinal choroid structure of the mouse treated by TAPI-1 is more complete, the fundus lesion area is less, the damage degree of the pigment epithelium and the photoreceptor cell is lighter, and the expression level of the inflammatory molecules in the ocular tissue is lower, and the treatment effect is significant. The application firstly proposes that TAPI-1 is used for preparing a drug for treating and / or preventing dry age-related macular degeneration, a new treatment strategy is provided for the dry age-related macular degeneration, and the application has a wide application prospect.

This invention provides an auxiliary device for lacrimal duct prosthesis placement in cases of lacrimal punctum stenosis. The device includes a guide tube and a tapered guide head located at the lower end of the guide tube. The guide tube comprises a left half and a right half disposed opposite each other, with an elastic clamping portion connected above the left and right half tubes. The left and right half tubes are openable and closeable via the elastic clamping portion. An arc-shaped left groove and a right groove are formed along the length direction on opposite sides of the left and right half tubes, respectively. The left and right grooves can be joined to form a receiving cavity. The tapered guide head includes a left guide head and a right guide head connected to the lower ends of the left and right half tubes, respectively. The left and right guide heads can be closed and connected. Compared to existing lacrimal duct prosthesis implantation aids, this invention's lacrimal duct prosthesis placement auxiliary device is simple to operate and allows for gentle, stepwise expansion, effectively reducing damage to ocular tissues.

Disclosed are devices and methods for directed delivery of a medicament into ocular tissue. A device for delivering a medicament to ocular tissue may include a housing, a container configured to contain the medicament, and a needle in fluid communication with the container, and a carriage positioned within the housing and coupled to the container and the needle. The carriage may be translatable along the needle axis and the carriage may include a threaded outer surface. The device may further include a nut positioned within the housing and engaged with the threaded outer surface. Rotation of the nut may be configured to cause the carriage and the needle to translate in a distal direction along the needle axis.

The present invention relates to use of a recombinant type III humanized collagen and a composition comprising the same in an eye. Provided are use of a recombinant type III humanized collagen in the preparation of a product for preventing and / or treating eye inflammation, a composition comprising the recombinant type III humanized collagen, and use of the composition in the preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant type III humanized collagen and the composition comprising the same can significantly promote the renewal and repair of corneal epithelial cells, and can also inhibit the release of inflammatory mediators, enhancing the ocular tissue barrier, enhancing tear film stability, and alleviating eye inflammation and eye dryness.

Disclosed are systems, devices and methods for laser microporation for rejuvenation of tissue of the eye, for example, regarding aging of connective tissue and rejuvenation of connective tissue by scleral rejuvenation. The systems, devices and methods disclosed herein restore physiological functions of the eye including restoring physiological accommodation or physiological pseudo-accommodation through natural physiological and biomechanical phenomena associated with natural accommodation of the eye. In some embodiments, the laser system may be configured to treat ocular tissue off axis or in a region of the eye which is distinct from the visual axis or directed away from the pupil of the eye where the gaze of the eye is.

Systems and methods are provided for measuring the mechanical properties of ocular tissue, such as the lens or cornea, for both diagnosis and treatment monitoring. A laser blocking feedback system is included to achieve frequency accuracy and sensitivity, facilitating highly precise operations and diagnosis. Differential comparisons between regions of ocular tissue in a patient, whether in the same eye or the contralateral eye, can further facilitate early diagnosis and monitoring.

In one aspect, the disclosure relates to clearing compounds capable of rendering at least one tissue transparent for a period of time, compositions comprising the same, pendant molecules bonded to the compounds capable of covalently or non-covalently binding to tissue such as collagen mimetic peptide, and macromolecules derivatized with the same. In another aspect, the compositions can be useful in clinic for visualizing internal anatomical structures and / or for clearing opacities of the eye. In one aspect, the compositions are topical, e.g., eye drops, lotions, or creams, or are injectable. In some aspects, an injection is performed directly into opaque tissue such as neural tissue, connective tissue, internal organs, ocular tissue, or the like. In other aspects, the clearing compound is injected adjacent to the target structure. The clearing compounds can be colorless across the entire visible spectrum, are non-toxic, and are excreted by the subject after visualization of tissue structures.

A method for constructing a personalized human eye model. This includes the following steps: (1) simplifying the structural parameters of the human eye to establish a personalized three-dimensional full-eye geometric model; (2) determining the viscoelastic material parameters of the human cornea; (3) using fluid-structure interaction to simulate the actual boundary conditions of the human eye, analyzing the changes in the actual state of the human eye, selecting appropriate element types, discretizing the model into a finite number of aggregates, completing the construction of the finite element human eye model, and solving the model using finite elements; (4) simulating optical coherence elastography of the anterior segment tissues such as the cornea. Considering the individual differences in the geometric morphology and tissue material parameters of the human eye, based on clinical ophthalmological diagnostic data, a personalized full-eye model containing complete geometric morphological information of the human eye was established in finite element software using an elastography method, providing theoretical guidance and technical support for ocular tissue optical coherence elastography equipment.

Disclosed are devices and methods for delivering a sheet of tissue into the eye in such a way that damage to the tissue is minimized, damage to the eye during insertion and manipulation of the tissue is minimized, and the tissue is released and delivered in a precise and controlled fashion.

The invention relates to an ophthalmic liposomal formulation for topical use that improves paracellular penetration of therapeutic agents such as aflibercept in the eyeball. The formulation includes an optimised mixture of liposomes, non-ionic solubilisers and excipients to facilitate the transport of the drug through the cornea and the controlled release thereof in the posterior segment of the eye. The formulation uses liposomes as a transport system, maximising the ocular bioavailability of aflibercept by means of a synergic combination of emulsifiers and stabilisers, allowing efficient penetration through the corneal barrier and sustained release of the drug in the eye tissue.

A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprises: a polymeric film has sufficient dimensions to cover a cornea when applied to an eye and the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.